Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL R SAPER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Pain Medicine

NPI
1891888095
CMS profile
358295
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$867.79

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $742.80 3
Food and Beverage $124.99 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Promius Pharma LLC $720.40 2
Lundbeck LLC $147.39 2

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL R SAPER

NPI 1891888095 · CMS profile ID 358295

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Pain Medicine

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $867.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $22.4011/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684345371 CMS
Lundbeck LLC $124.9911/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684345377 CMS
Promius Pharma LLC $574.4002/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701097285 CMS
Promius Pharma LLC $146.0001/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701097283 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $867.79 4
PY2024 $34.38 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $741,643.58 208
PY2024 Principal investigator $778,871.45 258
PY2023 Recipient $188,670.14 42
PY2023 Principal investigator $817,852.03 284
PY2022 Recipient $694.00 1
PY2022 Principal investigator $856,999.67 290
PY2021 Principal investigator $1,105,932.40 208
PY2020 Principal investigator $729,753.82 96
PY2019 Recipient $20,043.40 4
PY2019 Principal investigator $688,115.98 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

291 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $766.00 12/31/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL IN
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 889827923
Principal investigator 1 ABBVIE INC. $250.00 12/31/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL IN
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 965540333
Principal investigator 1 ABBVIE INC. $231.75 12/31/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL IN
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 965540335
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $500.00 12/28/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933403335
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,309.20 12/28/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933403337
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 12/23/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347755
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,160.00 12/22/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention No dispute reported 06/30/2026 933403187
Principal investigator 1 ABBVIE INC. $5,000.00 12/21/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 889826451
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 12/21/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347497
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,775.05 12/21/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347597
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $705.85 12/21/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347749
Principal investigator 1 H. Lundbeck A S $1,199.14 12/20/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945723621
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $8,445.25 12/15/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933403111
Principal investigator 1 Currax Pharmaceuticals LLC $3,000.00 12/15/2022 Non-covered Recipient Entity
Michigan Headache & Neurological Institute
17-AVP-825-301_Clinical Operations No dispute reported 06/30/2026 925763551
Principal investigator 1 H. Lundbeck A S $33.75 12/14/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1179407189
Principal investigator 1 H. Lundbeck A S $27.00 12/14/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine No dispute reported 06/30/2026 1179407191
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 12/14/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347487
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,205.00 12/14/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347493
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,886.55 12/14/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347737
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 12/14/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347743
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $10,613.40 12/08/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention No dispute reported 06/30/2026 933402989
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,154.25 12/06/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347731
Principal investigator 1 ABBVIE INC. $6,691.50 12/05/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889823049
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,095.45 12/01/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347481
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $500.00 11/29/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933402819
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,194.71 11/29/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933402821
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $281.21 11/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 907467237
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,592.00 11/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933402637
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $40.50 11/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933402641
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,847.49 11/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933402643
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,359.16 11/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933402645
Principal investigator 1 H. Lundbeck A S $1,250.44 11/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1179407123
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,975.40 11/22/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347475
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,095.45 11/22/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347591
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,808.80 11/22/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347725
Principal investigator 1 ABBVIE INC. $247.18 11/17/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889821491
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 11/15/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347585
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,579.00 11/15/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347719
Principal investigator 1 H. Lundbeck A S $1,449.22 11/13/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945723495
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 11/10/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347873
Principal investigator 1 H. Lundbeck A S $27.00 11/09/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine No dispute reported 06/30/2026 1179407079
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 11/08/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347869
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 11/08/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347967
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 11/08/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347973
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 11/08/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347979
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 11/08/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347985
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $26,175.78 11/03/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933402153
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $11,903.20 11/03/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention No dispute reported 06/30/2026 933402155
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 11/02/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347463
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,948.00 11/02/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347469
Principal investigator 1 ABBVIE INC. $5,462.25 11/01/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889817867
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $500.00 10/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933401949
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $13,687.48 10/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933401951
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $10,495.60 10/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention No dispute reported 06/30/2026 933401953
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 10/26/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347457
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,776.50 10/26/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347707
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 10/26/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347713
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $108.00 10/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 907467101
Principal investigator 1 H. Lundbeck A S $818.24 10/21/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1179407031
Principal investigator 1 H. Lundbeck A S $3,060.05 10/21/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine No dispute reported 06/30/2026 1179407033
Principal investigator 1 H. Lundbeck A S $818.24 10/21/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine No dispute reported 06/30/2026 1179407035
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,160.00 10/20/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention No dispute reported 06/30/2026 933401631
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $363.15 10/20/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933401633
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,000.00 10/20/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933401635
Principal investigator 1 H. Lundbeck A S $454.95 10/19/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945723445
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 10/18/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347579
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,040.70 10/18/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347701
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,250.00 10/13/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933401357
Principal investigator 1 H. Lundbeck A S $1,300.81 10/12/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1179407011
Principal investigator 1 H. Lundbeck A S $87.75 10/12/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1179407013
Principal investigator 1 H. Lundbeck A S $2,000.00 10/12/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine No dispute reported 06/30/2026 1179407015
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,190.90 10/07/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347443
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $81.00 10/07/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347451
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 10/07/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347863
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 10/07/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347957
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 10/07/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347961
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $202.50 10/06/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933401259
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $121.50 10/06/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933401261
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,888.00 10/06/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933401263
Principal investigator 1 ABBVIE INC. $4,233.00 10/05/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889813093
Principal investigator 1 H. Lundbeck A S $1,000.00 09/29/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 945723251
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $10,423.40 09/28/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention No dispute reported 06/30/2026 933401049
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,310.72 09/28/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933401051
Principal investigator 1 H. Lundbeck A S $8,267.00 09/28/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOG
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1179406979
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,840.15 09/28/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347695
Principal investigator 1 H. Lundbeck A S $750.00 09/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 945723235
Principal investigator 1 H. Lundbeck A S $6,000.00 09/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOG
Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine No dispute reported 06/30/2026 1179406973
Principal investigator 1 H. Lundbeck A S $533.25 09/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOG
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1179406975
Principal investigator 1 H. Lundbeck A S $555.32 09/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945723122
Principal investigator 1 H. Lundbeck A S $439.90 09/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945723131
Principal investigator 1 ABBVIE INC. $214.07 09/22/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889812205
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $5,918.10 09/22/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933400641
Principal investigator 1 H. Lundbeck A S $454.95 09/22/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945723113
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 09/20/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347573
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,392.55 09/20/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347689
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 09/20/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347857
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 09/20/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347951
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,817.77 09/15/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933400343
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,680.30 09/09/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347685
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $81.00 09/08/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933399839
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $14,109.41 09/08/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933399845
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $8,259.30 09/08/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention No dispute reported 06/30/2026 933399853
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,195.36 09/08/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933399859
Principal investigator 1 ABBVIE INC. $9,480.00 08/24/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889807481
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 08/23/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347437
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,807.35 08/23/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347567
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,456.80 08/23/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347679
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $702.50 08/18/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933398233
Principal investigator 1 H. Lundbeck A S $6,253.48 08/17/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOG
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1179406905
Principal investigator 1 H. Lundbeck A S $2,276.10 08/17/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOG
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1179406907
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,327.50 08/17/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347673
Principal investigator 1 H. Lundbeck A S $2,440.60 08/15/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945723037
Principal investigator 1 H. Lundbeck A S $357.75 08/12/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOG
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1179406899
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,372.06 08/11/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933397239
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,310.72 08/11/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933397247
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $13,602.19 08/11/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933397267
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $500.00 08/04/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933396585
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,600.60 08/04/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention No dispute reported 06/30/2026 933396595
Principal investigator 1 H. Lundbeck A S $954.45 08/04/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406859
Principal investigator 1 H. Lundbeck A S $801.90 08/04/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406861
Principal investigator 1 H. Lundbeck A S $1,432.66 08/04/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406863
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 08/04/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347851
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 08/04/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347945
Principal investigator 1 ABBVIE INC. $4,409.25 08/02/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889802961
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,455.40 08/02/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347667
Principal investigator 1 ABBVIE INC. $600.00 07/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 889802277
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $405.00 07/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933395613
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,039.17 07/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933395623
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $887.49 07/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933395633
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 07/27/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347563
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,621.65 07/27/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347661
Principal investigator 1 H. Lundbeck A S $1,000.00 07/26/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 945723007
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $363.15 07/21/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933394363
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $5,393.57 07/21/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933394373
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $12,367.89 07/21/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933394385
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,095.45 07/21/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347425
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 07/21/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347431
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 07/21/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347789
Principal investigator 1 ABBVIE INC. $202.50 07/15/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889801301
Principal investigator 1 ABBVIE INC. $500.00 07/14/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL IN
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 889800473
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $702.50 07/14/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933393557
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 07/12/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347845
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 07/12/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347939
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,103.40 07/08/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347557
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,186.03 07/07/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933392375
Recipient Eli Lilly and Company $694.00 07/01/2022 Covered Recipient Physician A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 917810945
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $1,500.00 07/01/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 907466683
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $1,500.00 07/01/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 907466693
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,911.15 06/30/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347649
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 06/30/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347655
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,082.85 06/28/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933392123
Principal investigator 1 H. Lundbeck A S $4,690.11 06/28/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406787
Principal investigator 1 Currax Pharmaceuticals LLC $500.00 06/24/2022 Non-covered Recipient Entity
Michigan Headache & Neurological Institute
17-AVP-825-301_Clinical Operations No dispute reported 06/30/2026 925763549
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $11,890.60 06/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933391399
Principal investigator 1 H. Lundbeck A S $135.00 06/23/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406757
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 06/21/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347839
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 06/21/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347921
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 06/21/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347927
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 06/21/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347933
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,896.00 06/20/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347419
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 06/17/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347833
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 06/17/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347915
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $500.00 06/09/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933389591
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,310.72 06/09/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933389599
Principal investigator 1 H. Lundbeck A S $750.00 06/02/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406731
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,095.45 06/02/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347551
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,161.25 06/02/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347645
Principal investigator 1 ABBVIE INC. $3,501.00 05/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL IN
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 889793043
Principal investigator 1 ABBVIE INC. $12,000.00 05/26/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 889792877
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $13,049.43 05/26/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933388687
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 05/25/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347545
Principal investigator 1 H. Lundbeck A S $2,556.02 05/24/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406727
Principal investigator 1 H. Lundbeck A S $2,556.02 05/24/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945722147
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,975.40 05/19/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347539
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,500.00 05/12/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933387161
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,195.36 05/12/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933387169
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $750.00 05/10/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 907466491
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,033.00 05/05/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347639
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 05/05/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347827
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 05/05/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347909
Principal investigator 1 H. Lundbeck A S $454.95 05/03/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406697
Principal investigator 1 H. Lundbeck A S $1,000.00 05/03/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406699
Principal investigator 1 H. Lundbeck A S $454.95 05/03/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945721773
Principal investigator 1 H. Lundbeck A S $1,000.00 05/03/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945721783
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,173.15 04/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933386387
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $7,000.00 04/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention No dispute reported 06/30/2026 933386395
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,167.30 04/27/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347533
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $810.00 04/27/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347633
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,550.00 04/21/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933384947
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $148.87 04/21/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 907466485
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,082.85 04/14/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933384475
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $9,594.24 04/14/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933384481
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 04/13/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347527
Principal investigator 1 H. Lundbeck A S $439.90 04/12/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406633
Principal investigator 1 H. Lundbeck A S $439.90 04/12/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945721347
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $11,722.43 04/07/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933384059
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,808.80 04/07/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347627
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,844.00 04/05/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347413
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 03/31/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347521
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,583.65 03/31/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347621
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $15,146.48 03/30/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933383367
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $440.40 03/29/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347515
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $33.75 03/29/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347615
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,005.75 03/24/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933382770
Principal investigator 1 Amgen Inc. $349.88 03/23/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Erenumab (EMBRACE) No dispute reported 06/30/2026 942841275
Principal investigator 1 Allergan, Inc. $1,000.00 03/17/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864375169
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $607.50 03/17/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933382437
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,190.90 03/17/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347509
Principal investigator 1 H. Lundbeck A S $1,468.46 03/15/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406557
Principal investigator 1 H. Lundbeck A S $555.32 03/15/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406559
Principal investigator 1 H. Lundbeck A S $2,343.13 03/15/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179406561
Principal investigator 1 H. Lundbeck A S $555.32 03/15/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945720875
Principal investigator 1 H. Lundbeck A S $1,468.46 03/15/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 945720883
Principal investigator 1 H. Lundbeck A S $2,343.13 03/15/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 945720939
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,231.90 03/10/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347603
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $750.00 03/10/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347609
Principal investigator 1 Eli Lilly and Company $92,885.00 03/09/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 917827141
Principal investigator 1 Allergan, Inc. $6,993.85 03/08/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864374217
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 03/04/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347821
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $750.00 03/03/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347185
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,095.45 03/03/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347197
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $440.40 03/03/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347503
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $750.00 03/03/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347783
Principal investigator 1 H. Lundbeck A S $33.75 03/01/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406533
Principal investigator 1 H. Lundbeck A S $33.75 03/01/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406535
Principal investigator 1 H. Lundbeck A S $1,000.00 03/01/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179406537
Principal investigator 1 H. Lundbeck A S $33.75 03/01/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945720529
Principal investigator 1 H. Lundbeck A S $33.75 03/01/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 945720539
Principal investigator 1 H. Lundbeck A S $1,000.00 03/01/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 945720549
Principal investigator 1 Allergan, Inc. $2,226.80 02/28/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864371493
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $5,894.36 02/24/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933380877
Principal investigator 1 H. Lundbeck A S $1,097.75 02/24/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406517
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $913.15 02/24/2022 Non-covered Recipient Entity
MRA CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 907466923
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $36.45 02/18/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347179
Principal investigator 1 Allergan, Inc. $9,242.55 02/17/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864370569
Principal investigator 1 H. Lundbeck A S $1,810.89 02/15/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179406511
Principal investigator 1 H. Lundbeck A S $1,810.89 02/15/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 945720137
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $750.00 02/10/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933380299
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,873.15 02/10/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347249
Principal investigator 1 Amgen Inc. $3,204.31 02/08/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 942841629
Principal investigator 1 H. Lundbeck A S $2,000.70 02/08/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406485
Principal investigator 1 H. Lundbeck A S $401.42 02/08/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406487
Principal investigator 1 H. Lundbeck A S $2,000.70 02/08/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945719877
Principal investigator 1 H. Lundbeck A S $401.42 02/08/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 945719887
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $750.00 02/03/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 933379145
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 02/03/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347815
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 02/03/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347891
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 02/03/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347897
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 02/03/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347903
Principal investigator 1 H. Lundbeck A S $750.00 02/01/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406481
Principal investigator 1 H. Lundbeck A S $33.75 02/01/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406483
Principal investigator 1 H. Lundbeck A S $750.00 02/01/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945719809
Principal investigator 1 H. Lundbeck A S $33.75 02/01/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 945719819
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 02/01/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347809
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 02/01/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347885
Principal investigator 1 Amgen Inc. $1,417.24 01/31/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 942843703
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,649.43 01/28/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933378345
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,000.00 01/28/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933378631
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,221.10 01/28/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933378639
Principal investigator 1 ABBVIE INC. $9,000.00 01/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (ICHD 2018). Migraine can be further categorized according to the frequency of attacks as episodic migraine (EM) or chronic migraine (CM). This study will assess the effects of BOTOX in preventing migraine in adult participants with EM. No dispute reported 06/30/2026 889774985
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $9,090.36 01/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933378059
Principal investigator 1 H. Lundbeck A S $7,620.00 01/27/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETIC STUDY TO EVALUATE IV EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH MIGRAINE, FOLLOWED BY AN OPTIONAL, MULTIPLE-DOSE, OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1179406455
Principal investigator 1 Amgen Inc. $11,551.23 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study No dispute reported 06/30/2026 942843399
Principal investigator 1 Amgen Inc. $500.00 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 942843701
Principal investigator 1 H. Lundbeck A S $101.25 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406439
Principal investigator 1 H. Lundbeck A S $96.18 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1179406441
Principal investigator 1 H. Lundbeck A S $353.70 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406443
Principal investigator 1 H. Lundbeck A S $961.20 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406445
Principal investigator 1 H. Lundbeck A S $101.25 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406447
Principal investigator 1 H. Lundbeck A S $101.25 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945719719
Principal investigator 1 H. Lundbeck A S $961.20 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 945719731
Principal investigator 1 H. Lundbeck A S $101.25 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 945719739
Principal investigator 1 H. Lundbeck A S $96.18 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 945719759
Principal investigator 1 H. Lundbeck A S $353.70 01/25/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945719799
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,290.00 01/25/2022 Non-covered Recipient Entity
ADVARRA INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED DOSE-RANGING TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF INTRAVENOUS MIJ821 INFUSION IN ADDITION TO COMPREHENSIVE STANDARD OF CARE ON THE RAPID REDUCTION OF SYMPTOMS OF MAJOR DEPRESSIVE DISORDER IN SUBJECTS W No dispute reported 06/30/2026 909388167
Principal investigator 1 Amgen Inc. $9,511.25 01/22/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 942841627
Principal investigator 1 Allergan, Inc. $203.00 01/19/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864368231
Principal investigator 1 H. Lundbeck A S $439.90 01/19/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1179406421
Principal investigator 1 H. Lundbeck A S $568.15 01/19/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOGICAL INSTITUTE
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 1179406423
Principal investigator 1 H. Lundbeck A S $568.15 01/19/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED DELAYED-START STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPTINEZUMAB IN PATIENTS WITH EPISODIC CLUSTER HEADACHE No dispute reported 06/30/2026 945719443
Principal investigator 1 H. Lundbeck A S $439.90 01/19/2022 Non-covered Recipient Entity
MICHIGAN HEAD-PAIN & NEUROLOG
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 945719483
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,509.00 01/17/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A 12 MONTHS PROSPECTIVE, INTERVENTIONAL, MULTINATIONAL, OPEN-LABEL, ACTIVE-CONTROLLED STUDY COMPARING SUSTAINED BENEFIT OF TWO TREATMENT PARADIGMS (ERENUMAB 140 MG QM VS ORAL PROPHYLACTICS) No dispute reported 06/30/2026 909408415
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $500.00 01/13/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933376883
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,000.00 01/13/2022 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933377165
Principal investigator 1 Allergan, Inc. $4,936.20 01/12/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864367251
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,264.20 01/12/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347237
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $33.75 01/12/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347243
Principal investigator 1 Eli Lilly and Company $1,435.00 01/05/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 917827465
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 01/05/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347801
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $665.00 01/05/2022 Non-covered Recipient Entity
Michigan Head Pain & Neurological Institute
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 942347879
Principal investigator 1 Amgen Inc. $9,088.62 01/04/2022 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study No dispute reported 06/30/2026 942843401